Navigation Links
Innocoll Announces Dosing of Last Patient in US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Cardiac Surgery Patients
Date:3/16/2009

ASHBURN, Va., March 16 /PRNewswire/ -- Innocoll, Inc., a privately-held biopharmaceutical company, announced that the last patient has been dosed in the first of two ongoing U.S. phase 3 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the prevention of surgical site infections.

The trial is being conducted at approximately 50 hospital sites across the U.S. and has enrolled 1,500 diabetic and/or obese (BMI>30) patients undergoing cardiac surgery. Such patients are generally recognized to be at higher risk of developing sternal wound infections (SWI); a serious and potentially life-threatening complication of cardiac surgery. Patients in the treatment group have two Gentamicin Implants (260 mg total dose) placed between the sternal halves before chest closure and the primary endpoint is total incidence of SWI after 3 months post-surgery. The trial design was based on a published 2,000 patient clinical trial performed in Sweden which demonstrated that the implant significantly reduced the incidence of sternal wound infection (SWI) by 53 percent, increasing to 68 percent reduction in the higher risk patient population. A health economic analysis of the Swedish study has also been published and concluded that routine prophylactic use of the Gentamicin Implant resulted in a net cost saving per patient.

Patient enrolment in a second phase 3 trial being conducted in patients undergoing open colorectal surgery is expected to close later this month. Innocoll has appointed Duke University's Duke Clinical Research Institute (DCRI) as the Study Coordinating Center for both phase 3 trials.

Dr. Michael Myers, Innocoll's President and CEO commented, "We are delighted to have completed patient enrolment in this phase 3 cardiac surgery trial, which we are running in parallel with the second phase 3 trial in colorectal s
'/>"/>

SOURCE Innocoll, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-Operative Pain
2. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Prevention of Diabetic Foot Infections
3. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers
4. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
5. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
6. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
7. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
8. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
9. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB PRESENTATIONS TO BE MADE AT THE 100TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AND EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY
10. Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
11. InteKrin Therapeutics Announces Enrollment Completion of 360 Patient, 24 week Phase 2b Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Boston Children,s Hospital,s Global Pediatric Summit + ... an "Innovation Tank" – a forum designed to give ... business or product solution to a panel of acclaimed ... to accelerate the innovation and bring it to market. ... October 31, will be moderated by Daymond John ...
(Date:7/24/2014)... , July 24, 2014  To help ... cardiovascular market that could impact patient care and ... 2014 CV Watch , "Innovations in Cardiovascular Devices."  ... hospitals with guidance and details on promising new ... needs and understand how these options impact the ...
(Date:7/24/2014)... part of its ongoing effort to help women pharmacists become ... Boot Camp on July 26 as part of the company,s ... The Boot Camp is designed to ... their own pharmacies.  Now in its third year, the Cardinal ... pharmacists who dream of owning a pharmacy.   ...
Breaking Medicine Technology:Taking on Tomorrow to Feature "Innovation Tank" Pitch Opportunity for Aspiring Pediatric Health Care Entrepreneurs 2Taking on Tomorrow to Feature "Innovation Tank" Pitch Opportunity for Aspiring Pediatric Health Care Entrepreneurs 3New Novation CV Watch Shows Recent Technology Innovations Could Drive Cardiovascular Product Costs Up by as Much as 35 Percent 2New Novation CV Watch Shows Recent Technology Innovations Could Drive Cardiovascular Product Costs Up by as Much as 35 Percent 3'Women in Pharmacy' Program Seeks to Expand Pharmacy Ownership 2'Women in Pharmacy' Program Seeks to Expand Pharmacy Ownership 3'Women in Pharmacy' Program Seeks to Expand Pharmacy Ownership 4
... Association of Clinical Research Organizations (ACRO), which represents the ... and the public in the U.S. and worldwide, issued ... Implications of the Globalization of Clinical Research" published in ... England Journal of Medicine : The article by ...
... Journal of Medicine employs Quest Diagnostics, blood-based leukemia testingMADISON, ... specimens may detect abnormal white blood cells in patients ... develops, according to research published in the current issue ... Medicine . The finding may lead to a better ...
Cached Medicine Technology:ACRO Comments on NEJM Article on Globalization of Clinical Research 2ACRO Comments on NEJM Article on Globalization of Clinical Research 3Blood Testing Identifies Abnormal Cells Up to Six Years Prior to Leukemia Diagnosis 2Blood Testing Identifies Abnormal Cells Up to Six Years Prior to Leukemia Diagnosis 3Blood Testing Identifies Abnormal Cells Up to Six Years Prior to Leukemia Diagnosis 4
(Date:7/24/2014)... A new study led by the Translational Genomics Research ... viruses and the immune system during HIV infection. , ... to infect others based on their blood viral ... in their semen despite having low levels in their ... the virus can be found in different parts of ...
(Date:7/24/2014)... London, UK (PRWEB) July 24, 2014 Memantine ... and was first marketed in Germany under the brand name ... and other nations as Ebixa and in the USA to ... of USD 420 million in 2013. In the US, Forest ... , Patent protection expiry in Canada, Australia and the European ...
(Date:7/24/2014)... 24, 2014 Members of the Iowa State ... CCIM, Senior Associate of Sales at OutcomesMTM, as their Chairperson. ... to the Board and that his peers chose to keep ... provide the best I can for the citizens of Iowa,” ... positioned to provide a special insight to concerns and issues ...
(Date:7/24/2014)... In a recent report by CBS News, the district capital ... criminal penalties associated with possession of small amounts of marijuana. ... Washington DC, giving it one of the most tolerant marijuana ... possession of one ounce of marijuana or less with a ... an ounce of marijuana remain criminal offenses under the new ...
(Date:7/24/2014)... received the Human Papillomavirus Vaccination (HPV) even after ... Pap test results than those who were never ... Sexually Transmitted Diseases . , Researchers from ... of Medicine conducted a cross-sectional study of 235 ... cytology testing. HPV status and demographic and behavioral ...
Breaking Medicine News(10 mins):Health News:TGen-led study seeks to understand why some HIV-positive men are more infectious 2Health News:Memantine Discussed in New Comprehensive Patent Search Report by Ark Patent Intelligence Published at MarketPublishers.com 2Health News:Memantine Discussed in New Comprehensive Patent Search Report by Ark Patent Intelligence Published at MarketPublishers.com 3Health News:Wolnerman Re-elected as Chairperson of Iowa State Board of Health 2Health News:Washington D.C. Decriminalizes Marijuana 2
... Pilot animal study shows promising results in the treatment of ... ... (Vocus) September 9, 2008 -- A pilot animal ... Boston] provides preliminary evidence that delivering neural stem cells (NSC) ...
... WEXFORD, Penn., Sept. 9 Millennium Pharmacy Systems,Inc., ... enabled pharmacy,solutions to senior healthcare facilities, announced today ... Mr. Scardina has served on,the Millennium Board of ... as an independent consultant after serving as an ...
... TARRYTOWN, N.Y., Sept. 9 Focus 28, Inc. ... its new next generation line of,meal replacements and ... of bariatric patients. According to the company,Bariatric RX ... food,supplements also utilize Double A Technology (AAT), a ...
... Mark Jones and William Reed with colleagues at the ... use of Tasers related to ethnicity, gender, race and ... the Use of Conducted Energy Devices by the Houston ... "Conducted Energy Device Program Performance Audit," released by the ...
... 9 Governor Edward G.,Rendell today announced the ... as Secretary of the Pennsylvania Department of Health ... passionate voice for protecting and improving,the health of ... as an effective leader, addressing a variety of,issues ...
... for the Retirement ... month, NORTH CONWAY, N.H., Sept. 9 It,s no ... aging population grows, so,does the need to house them. According ... nursing homes, 39,500 assisted living,facilities and 1,900 continuing care retirement ...
Cached Medicine News:Health News:Neural Stem Cells May Help Repair Spina Bifida in Utero 2Health News:Neural Stem Cells May Help Repair Spina Bifida in Utero 3Health News:Neural Stem Cells May Help Repair Spina Bifida in Utero 4Health News:Focus 28 Begins Shipping Next Generation Line of Meal Replacements and Food Supplements for Bariatric Patients 2Health News:Rice political scientists co-author report on ethnic/racial aspects of Taser use by Houston police 2Health News:Governor Rendell Announces Resignation of Health Secretary Dr. Calvin Johnson 2Health News:SeniorHousingJobs.com Celebrates Its 5th Anniversary 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: